UNSPSC 51352431: Estrone/testosterone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS900. This VA Drug Class (HS900) classifies this compound as belonging to the group HORMONES/SYNTHETICS/MODIFIERS, OTHER.

UNSPSC 51352431 Estrone/testosterone is a Commodity code covering hormone replacement and therapeutic pharmaceutical products procured by state health and human services agencies and multistate cooperative purchasing groups. State and local buyers under this code include health departments, pharmacy benefit administrators, and cooperative purchasing alliances that source pharmaceuticals for state employee health plans, Medicaid programs, and institutional healthcare settings. The work involves establishing supply contracts with manufacturers for generic and branded hormone therapeutics, negotiating pricing and distribution terms with wholesalers, and managing compliance with FDA manufacturing standards and drug supply chain security requirements.

Recent activity centers on Texas and Minnesota. The Texas Health and Human Services Commission posted Request for Information No. HHS0017013 in March 2026 (response deadline April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information from manufacturers on direct contracting capacity, negotiated net pricing models, and value-based outcomes agreements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued Request for Proposal S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon. MMCAP requires product delivery through AmerisourceBergen, Cardinal Health, or Morris & Dickson; awards take effect July 1, 2026. Evaluation heavily weights price competitiveness (75 percent), with smaller weight given to fixed pricing, EDI capability, administrative compliance, and pricing format flexibility. Vendors must maintain $5 million commercial general liability coverage, certify cGMP and DSCSA compliance, and accept a 3 percent administrative fee on all purchases.